XML 88 R59.htm IDEA: XBRL DOCUMENT v3.22.2
Sale of Future Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 17 Months Ended
Nov. 03, 2020
Apr. 01, 2016
Nov. 30, 2020
Dec. 31, 2020
Jun. 30, 2022
Jun. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2022
Disaggregation of Revenue [Line Items]                      
Payments for loan acquisition costs                 $ 2,909    
Revenues         $ 13,265 $ 15,345     25,535 $ 26,467  
Royalty                      
Disaggregation of Revenue [Line Items]                      
Revenues                 (823)    
MAM Pangolin Royalty , LLC | Maximum                      
Disaggregation of Revenue [Line Items]                      
Proceeds from sale of future revenue $ 125,000                    
License agreement with Sunovion Pharmaceuticals, Inc.                      
Disaggregation of Revenue [Line Items]                      
Revenues   $ 22,000                  
Minimum annual royalty receivable         $ 1,000   $ 1,000   $ 1,000    
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty                      
Disaggregation of Revenue [Line Items]                      
Revenues             $ 8,000 $ 8,000      
Monetization agreement                      
Disaggregation of Revenue [Line Items]                      
Effective annual interest rate 24.90%                    
Monetization agreement | MAM Pangolin Royalty , LLC                      
Disaggregation of Revenue [Line Items]                      
Proceeds from sale of future revenue $ 40,000     $ 10,000             $ 50,000
Proceeds from debt, contingent on additional milestones     $ 75,000